|
With a $200 million investment over five years to address TB, the leading cause of death worldwide from an infectious disease (only surpassed by COVID-19 in 2020), the consortium will leverage diverse fields of TB research and leadership, and will prioritize studies to improve TB detection methods, treatments, containment and control strategies, and prevention with vaccines.
At least 60 percent of the funds will support five hubs in USAID's 24 priority high TB burden countries to build research capacity and leadership at local, regional, and national governments, health institutions and support organizations. Along with Johns Hopkins Medicine, the consortium includes KNCV Tuberculosis Foundation, Elizabeth Glaser Pediatric AIDS Foundation, and Treatment Action Group. Read more here.
The UCSF Team in the SMART4TB Consortium will include: Payam Nahid, MD, MPH as UCSF Project Director and UCSF Technical Leads Adithya Cattamanchi, MD; Phil Hopewell, MD; Eric Goosby, MD; Mike Reid, MBBS, MPH; Lisa Chen, MD; Patrick Phillips, PhD; Gabriel Chamie, MD; Gustavo Velásquez, MD, MPH; Devan Jaganath, MD, MPH; Priya Shete, MD, MPH; Carina Marquez, MD, MPH; Andrew Kerkhoff, MD, PhD; and Claudia Denkinger, MD, PhD of Heidelberg University.
| 
